Intelligence Platform

Patents

Browse 376 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 10465194

Complement component iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10407679

Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 10 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 05 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400239

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10400238

Polynucleotide agents targeting complement component C5 and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Sep 03 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 29 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10369226

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10370666

Ketohexokinase (KHK) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Aug 06 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 01 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10337010

Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Jul 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 27 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10273477

Therapeutic compositions

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 30 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 25 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10266484

Biodegradable lipids for the delivery of active agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 23 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 18 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10246713

TMPRSS6 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10246708

Dosages and methods for delivering lipid formulated nucleic acid molecules

Alnylam Pharmaceuticals, Inc. · Granted Tue Apr 02 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10238749

Angiotensinogen (AGT) iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10240152

Compositions and methods for inhibiting expression of transthyretin

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10231988

Patatin-like phospholipase domain containing 3 (PNPLA3) iRNA compositions and methods of u

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233448

Modified double-stranded RNA agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10233452

Compositions and methods for increasing erythropoietin (EPO) production

Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10208307

Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventin

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10195291

Compositions and methods for the manufacture of lipid nanoparticles

Alnylam Pharmaceuticals, Inc. · Granted Tue Feb 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10190118

Methods and compositions for treating insects

Alnylam Pharmaceuticals, Inc. · Granted Tue Jan 29 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 24 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10131907

Glycoconjugates of RNA interference agents

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10125369

PCSK9 iRNA compositions and methods of use thereof

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10119143

Compositions and methods for inhibiting expression of the ALAS1 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Nov 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10100312

Compositions and methods for inhibiting expression of TMPRSS6 gene

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 16 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 11 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 10086081

Carbohydrate conjugated RNA agents and process for their preparation

Alnylam Pharmaceuticals, Inc. · Granted Tue Oct 02 2018 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 27 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted